SV debuts a new, $400M fund with a big focus on biotech startups
After tweaking its name, SV Health Investors unveiled its sixth main fund with $400 million, a step down from its last big raise way back in 2010.
SV is best known for its biotech plays as an active investor in the startup community. But the venture firm also targets medical devices, digital health and healthcare services, which is one reason it dropped Life Sciences from the name.
SV has offices rooted in the three big global hubs: London, Cambridge, MA and San Francisco. It has backed companies like Micromet — bought out by Amgen for $1.16 billion — along with Incyte, Achillion and Shire in the early days. Its current investments include Sutro, Kalvista and Catabasis, which has had to grapple with some recent setbacks in the clinic, including a flop for Duchenne muscular dystrophy.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.